EMA Validates PolyPid's D-PLEX100 Marketing Application, Starting Formal EU Review
PYPD sits 73% above its 52-week low of $3.06 on light trading volume (0.2× avg).
Summary
PolyPid's D-PLEX100 marketing application has been validated by the EMA, formally starting the EU review process. The candidate is already under FDA Priority Review with a November 28, 2026 PDUFA date.
Key Events · Product Development and Regulatory · PYPD
-
EMA Validates D-PLEX100 MAA
The European Medicines Agency validated PolyPid's Marketing Authorization Application for D-PLEX100, confirming completeness and initiating formal review by the CHMP under the Centralized Procedure.
-
EU-Wide Approval Potential
If approved, D-PLEX100 would receive a single marketing authorization valid throughout all European Union member states, covering a significant SSI market.
-
Dual Regulatory Track
D-PLEX100 is concurrently under FDA Priority Review with a PDUFA goal date of November 28, 2026, positioning the candidate for potential approval in both the U.S. and EU.
-
European Rights Retained
PolyPid retains commercial rights to D-PLEX100 outside the U.S. and Canada following the mutual termination of the ADVANZ PHARMA European license announced earlier today, enabling new partnership negotiations.
Analysis · PYPD · Industrial Applications And Services
The EMA has validated PolyPid's Marketing Authorization Application for D-PLEX100, its lead surgical infection prevention candidate. Validation means the application is complete and now enters formal review by the CHMP under the Centralized Procedure — a key regulatory gate that, if passed, would grant a single marketing authorization across all EU member states. This comes on top of the FDA's Priority Review with a November 28, 2026 PDUFA date, putting D-PLEX100 on a dual-track approval path in the two largest pharmaceutical markets. The company retains European commercial rights after the ADVANZ PHARMA termination announced earlier today, so a successful EMA review would let PolyPid negotiate a new European partnership from a stronger position.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1625 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYPD was trading at $5.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $107M. The 52-week trading range was $3.06 to $5.73. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.